Divining progression in Parkinson disease with a blood test: NfL

In their article in this issue of Neurology®, Lin and colleagues1 provide compelling evidence for the utility of a neurofilament light chain (NfL) blood test in predicting progression in Parkinson disease (PD) and in distinguishing PD from multisystem atrophy (MSA). If confirmed by independent studies, this would be a major advance for clinical and basic research. Such a test also may have complex consequences for clinical care.

Source link

Related posts

CSF Protein Ratios May Predict Dementia in Parkinson Disease


Prosthetic Memory System Successful in Humans


What's happening in Neurology(R) Clinical Practice


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy